下肢关节置换术后药物性血栓预防与伤口渗液的关系
这项前瞻性、观察性、多中心研究纳入327例择期髋或膝关节置换患者,按血栓预防方案分为无抗凝组、阿司匹林组和低分子肝素(依诺肝素)组。使用低分子肝素者伤口渗液风险为无药物血栓预防者的4.92倍,阿司匹林者为3.64倍(P < .0001);组间深静脉血栓或肺栓塞发生率无显著差异。
要点
- 低分子肝素组伤口渗液风险为无抗凝组的4.92倍(P < .0001)。
- 阿司匹林组伤口渗液风险为无抗凝组的3.64倍(P < .0001)。
- 组间深静脉血栓或肺栓塞发生率无显著差异。
核心结论
- 在关节置换患者中,使用阿司匹林或低分子肝素时伤口渗液风险显著增加。
- 由于伤口问题的潜在并发症严重,为该患者群体处方血栓预防时需更平衡地权衡风险与获益。
研究设计与样本
- 前瞻性、观察性、多中心研究,纳入接受择期髋或膝关节置换的患者。
- 患者按血栓预防方案分为3组:无抗凝组、阿司匹林组、低分子肝素(依诺肝素)组。
- 使用Southampton伤口评估评分对手术伤口进行评估。
- 12个月期间共纳入327例患者,平均年龄68.1岁(±11.2岁)。
主要发现
- 无抗凝组105例(32.1%),阿司匹林组97例(29.7%),低分子肝素组125例(38.2%)。
- 低分子肝素组伤口渗液风险为无药物血栓预防组的4.92倍(P < .0001)。
- 阿司匹林组伤口渗液风险为无药物血栓预防组的3.64倍(P < .0001)。
- 组间住院期间或出院后深静脉血栓或肺栓塞发生率无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefits vs risk of pharmacological prophylaxis for thromboembolic disease in orthopedic patients remain controversial. Pharmacological thromboprophylaxis regimes are commonly used in this patient group. Few studies specifically examine wound complications attributable to this therapy. In this prospective trial, we investigated the effect of various regimens on postoperative wounds. METHODS: A prospective, observational, multicenter study involving patients undergoing elective hip or knee arthroplasty was undertaken. Patients were divided into 3 groups depending on thromboprophylaxis: no anticoagulation, aspirin, or low molecular weight heparin (LMWH) (enoxaparin). Surgical wounds were evaluated for each regime using the Southampton Wound Assessment Score. RESULTS: Over a 12-month period, 327 patients were enrolled with a mean age of 68.1 years (±11.2 years). There were 105 patients in the no anticoagulation group (32.1%), 97 patients in the aspirin group (29.7%), and 125 patients in the LMWH group (38.2%). Wound scores were evaluated for evidence and amount of discharge. The use of LMWH conferred a 4.92 times greater risk and aspirin a 3.64 times greater risk of wound discharge than no pharmacological thromboprophylaxis (P < .0001). There were no significant differences in the incidence of deep vein thrombosis or pulmonary embolus between groups either as an inpatient or postdischarge. CONCLUSION: There is a significant increase in the risk of wound discharge when aspirin or LMWH is used in arthroplasty patients. As potential complications of wound problems are significant, a more balanced view of risk vs benefit needs to be taken when prescribing thromboprophylaxis for this patient group.
引用
- Jones CW, Spasojevic S, Goh G, et al. Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty. J Arthroplasty. 2017. PMID: 28869115. doi:10.1016/j.arth.2017.07.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。